comparemela.com
Home
Live Updates
ImmunityBio Announces Biological License Application Resubmission for N-803 in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer Carcinoma-In-Situ : comparemela.com
ImmunityBio Announces Biological License Application Resubmission for N-803 in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer Carcinoma-In-Situ
Provides updated data on prolonged duration of complete response in BCG-Unresponsive and BCG-Naïve NMIBC patients
Following the Type A Meeting with the FDA, ImmunityBio has completed the BLA...
Related Keywords
Massachusetts ,
United States ,
,
Nasdaq ,
Exchange Commission ,
Health Authority Or Agency ,
Drug Administration ,
Massachusetts Medical Society ,
Immunitybio Inc ,
Company Form ,
Biologics License Application ,
Bacillus Calmette Gu ,
Health Authority ,
Unresponsive Non ,
Muscle Invasive Bladder ,
Massachusetts Medical ,
Long Term Clinical Outcomes ,
Pivotal Trial ,
Papillary Non Muscle Invasive Bladder Cancer ,
Unresponsive Non Muscle Invasive Bladder Cancer ,
Exceptional Responder ,
Nonmuscle Invasive Bladder Cancer ,
Case Series ,
Private Securities Litigation Reform Act ,
Complete Response Letter ,
Markets ,
comparemela.com © 2020. All Rights Reserved.